国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
International Journal of Respiration
2015年
15期
1152-1154
,共3页
急性加重期%慢性阻塞性肺疾病%低分子肝素%临床疗效
急性加重期%慢性阻塞性肺疾病%低分子肝素%臨床療效
급성가중기%만성조새성폐질병%저분자간소%림상료효
Acute exacerbation%Chronic obstructive pulmonary disease%Low molecular weight heparin%Clinical efficacy
目的 探讨早期应用低分子肝素对慢性阻塞性肺疾病急性加重期(AECOPD)的影响.方法 将本院2012年1月至2013年12月间60例COPD患者按照随机数字表法分为研究组与对照组,均30例.对照组应用常规治疗,研究组在常规治疗基础上应用低分子肝素治疗,观察2组的临床疗效.结果 研究组总有效率为93.3%,高于对照组的66.7%,差异有统计学意义(P<0.05);治疗后研究组与对照组凝血酶原时间、活化部分凝血活酶时间、血纤蛋白原、凝血酶时间、D-二聚体、FEV1% pred、FEV1/FVC较治疗前后有不同程度的改善,且研究组优于对照组(P<0.05).差异有统计学意义.结论 临床中对于AECOPD患者早期应用低分子肝素干预是可行的,改善血液高凝状态,值得临床中应用与推广.
目的 探討早期應用低分子肝素對慢性阻塞性肺疾病急性加重期(AECOPD)的影響.方法 將本院2012年1月至2013年12月間60例COPD患者按照隨機數字錶法分為研究組與對照組,均30例.對照組應用常規治療,研究組在常規治療基礎上應用低分子肝素治療,觀察2組的臨床療效.結果 研究組總有效率為93.3%,高于對照組的66.7%,差異有統計學意義(P<0.05);治療後研究組與對照組凝血酶原時間、活化部分凝血活酶時間、血纖蛋白原、凝血酶時間、D-二聚體、FEV1% pred、FEV1/FVC較治療前後有不同程度的改善,且研究組優于對照組(P<0.05).差異有統計學意義.結論 臨床中對于AECOPD患者早期應用低分子肝素榦預是可行的,改善血液高凝狀態,值得臨床中應用與推廣.
목적 탐토조기응용저분자간소대만성조새성폐질병급성가중기(AECOPD)적영향.방법 장본원2012년1월지2013년12월간60례COPD환자안조수궤수자표법분위연구조여대조조,균30례.대조조응용상규치료,연구조재상규치료기출상응용저분자간소치료,관찰2조적림상료효.결과 연구조총유효솔위93.3%,고우대조조적66.7%,차이유통계학의의(P<0.05);치료후연구조여대조조응혈매원시간、활화부분응혈활매시간、혈섬단백원、응혈매시간、D-이취체、FEV1% pred、FEV1/FVC교치료전후유불동정도적개선,차연구조우우대조조(P<0.05).차이유통계학의의.결론 림상중대우AECOPD환자조기응용저분자간소간예시가행적,개선혈액고응상태,치득림상중응용여추엄.
Objective To investigate the influence of early application of low molecular weight heparin aggravation of acute exacerbateion chronic obstructive pulmonary disease (AECOPD).Methods The hospital between January 2012 to December 2013 60 patients with AECOPD randomly divided according to the study group and the control group were 30 cases.The control group received conventional therapy,low molecular weight heparin therapy research group in the conventional treatment based on the clinical efficacy of the two groups were observed.Results The total effective rate was 93.3 %,66.7% higher than that,there are statistically significant (P <0.05);treatment after the study group and the control group PT,APTT,FBG,TT,DD,FEV1 % pred,FEV1 / FVC compared before and after treatment have improved to varying degrees,and the study group than the control group (P <0.05),a statistically meaningful.Conclusions The clinical for AECOPD of low molecular weight heparin in patients with early intervention possible,improve blood hypercoagulable state,worthy of clinical application and promotion.